MALAT1 in colorectal cancer: Its implication as a diagnostic, prognostic, and predictive biomarker

Gene. 2022 Nov 15:843:146791. doi: 10.1016/j.gene.2022.146791. Epub 2022 Aug 9.

Abstract

Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), originally described as a prognostic biomarker remarkably linked with metastasis potential in lung cancer, has been identified as contributing to many diseases, including colorectal cancer (CRC). This long non-coding RNA (lncRNA) has come to the forefront of lncRNA research for its implications in cancer-related processes, such as cell proliferation and migration. In general, lncRNAs are recognized as enhancers, scaffolds, or decoys for a variety of oncogenes and tumor suppressors, although our understanding of lncRNA functions and mechanisms of action is still limited. Nowadays, cancer research is attracted to lncRNAs' ability to improve the early diagnosis of cancer, determine patients' prognosis, or predict therapy outcomes. In this review, we aimed to evaluate recent publications trying to uncover the cellular mechanisms of MALAT1-mediated regulation, and its potential exploitation in the management of CRC. The conclusions of this review provide robust support for the essential role of MALAT1 in CRC development and future personalized therapy.

Keywords: Biomarker; Colorectal cancer; MALAT1; ceRNA; lncRNA.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Cell Line, Tumor
  • Colorectal Neoplasms* / diagnosis
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / pathology
  • Humans
  • Prognosis
  • RNA, Long Noncoding / genetics*

Substances

  • Biomarkers
  • MALAT1 long non-coding RNA, human
  • RNA, Long Noncoding